BSE Live
Mar 25, 16:01Prev. Close
36.55
Open Price
36.92
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 25, 15:57Prev. Close
36.55
Open Price
36.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
36.97 (4058)
| Profit & Loss account of Morepen Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 779.86 | 705.97 | 552.95 | 539.65 | 445.75 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 9.05 | |
| Revenue From Operations [Net] | 779.86 | 705.97 | 552.95 | 539.65 | 436.69 | |
| Total Operating Revenues | 791.99 | 717.24 | 560.83 | 547.51 | 452.46 | |
| Other Income | 9.42 | 3.67 | 3.54 | 3.72 | 1.17 | |
| Total Revenue | 801.40 | 720.91 | 564.37 | 551.23 | 453.64 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 413.22 | 343.08 | 220.53 | 226.00 | 181.59 | |
| Purchase Of Stock-In Trade | 115.45 | 142.74 | 117.83 | 124.18 | 102.27 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -7.58 | -19.46 | 4.24 | -14.44 | -4.46 | |
| Employee Benefit Expenses | 98.07 | 84.74 | 68.22 | 60.79 | 51.67 | |
| Finance Costs | 1.97 | 2.07 | 4.29 | 7.47 | 10.41 | |
| Depreciation And Amortisation Expenses | 34.43 | 38.01 | 33.40 | 33.56 | 34.92 | |
| Other Expenses | 108.36 | 101.12 | 89.74 | 90.49 | 57.19 | |
| Total Expenses | 763.92 | 692.30 | 538.26 | 528.06 | 433.59 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 37.48 | 28.61 | 26.12 | 23.17 | 20.04 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 37.48 | 28.61 | 26.12 | 23.17 | 20.04 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.00 | 2.13 | 0.00 | 3.51 | 3.38 | |
| Less: MAT Credit Entitlement | 0.00 | 2.13 | 0.00 | 3.51 | 3.38 | |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax For Earlier Years | 5.15 | 0.00 | 0.00 | 0.00 | -0.14 | |
| Total Tax Expenses | 5.15 | 0.00 | 0.00 | 0.00 | -0.14 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 32.33 | 28.61 | 26.12 | 23.17 | 20.18 | |
| Profit/Loss From Continuing Operations | 32.33 | 28.61 | 26.12 | 23.17 | 15.78 | |
| Profit/Loss For The Period | 32.33 | 28.61 | 26.12 | 23.17 | 15.78 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 0.72 | 0.64 | 0.58 | 0.52 | 0.35 | |
| Diluted EPS (Rs.) | 0.72 | 0.64 | 0.58 | 0.52 | 0.35 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 237.12 | 179.64 | 115.47 | 124.68 | 88.14 | |
| Indigenous Raw Materials | 176.10 | 163.44 | 105.36 | 101.32 | 93.45 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
16.03.2026
Morepen Lab Consolidated December 2025 Net Sales at Rs 484.16 crore, up 6.93% Y-o-Y
20.02.2026
Morepen Lab Consolidated December 2025 Net Sales at Rs 484.16 crore, up 6.93% Y-o-Y
19.02.2026
Morepen Lab Standalone December 2025 Net Sales at Rs 457.57 crore, up 13.47% Y-o-Y
26.11.2025
Morepen Lab Consolidated September 2025 Net Sales at Rs 411.58 crore, down 5.97% Y-o-Y
25.03.2026
25.03.2026
25.03.2026
24.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth